Publications for Josefine Bostner
Co-author map based on ISI articles 2007-

Publications mentioned in social media 9 times*

Journal Articles

Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Xavier Barril, Jordi Serra-Musach, Abul Islam, Livia Caizzi, Luciano Di Croce, Ekaterina Nevedomskaya, Wilbert Zwart, Josefine Bostner, Elin Karlsson, Gizeh Perez-Tenorio, Tommy Fornander, Dennis C Sgroi, Rafael Garcia-Mata, Maurice Phm Jansen, Nadia García, Núria Bonifaci, Fina Climent, María Teresa Soler, Alejo Rodríguez-Vida, Miguel Gil, Joan Brunet, Griselda Martrat, Laia Gómez-Baldó, Ana I Extremera, Agnes Figueras, Josep Balart, Robert Clarke, Kerry L Burnstein, Kathryn E Carlson, John A Katzenellenbogen, Miguel Vizoso, Manel Esteller, Alberto Villanueva, Ana B Rodríguez-Peña, Xosé R Bustelo, Yusuke Nakamura, Hitoshi Zembutsu, Olle Stål, Roderick L Beijersbergen and Miguel Angel Pujana
  VAV3 mediates resistance to breast cancer endocrine therapy
 
Altmetric usage: 6

  Breast Cancer Research, 2014, 16(3), R53.

Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck and Olle Stål
  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
 
Altmetric usage: 2

  Breast Cancer Research, 2013, 15(5), R96.
   Fulltext  PDF  
 Web of Science® Times Cited: 3

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
  Breast Cancer Research and Treatment, 2013, 137(2), 397-406.
 Web of Science® Times Cited: 10

Elin Karlsson, Marie Ahnström, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, Anna-Lotta Hallbeck and Olle Stål
  High-Resolution Genomic Analysis of the 11q13 Amplicon in Breast Cancers Identifies Synergy with 8p12 Amplification, Involving the mTOR Targets S6K2 and 4EBP1
 
Altmetric usage: 1

  Genes, Chromosomes and Cancer, 2011, 50(10), 775-787.
   Fulltext  PDF  
 Web of Science® Times Cited: 12

Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Estrogen Receptor-alpha Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
  Clinical Cancer Research, 2010, 16(5), 1624-1633.
   Fulltext  PDF  
 Web of Science® Times Cited: 19

Josefine Bostner, Marie Ahnström Waltersson, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stål
  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
  Oncogene, 2007, 26(49), 6997-7005.
 Web of Science® Times Cited: 52

Conference Articles

Josefine Bostner, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stal
  Estrogen Receptor alpha Phosphorylation on Serine 305, p21-Activated Kinase 1 and Tamoxifen Response in Postmenopausal Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-596S
  CANCER RESEARCH, 2009.


E Karlsson, M A Waltersson, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, T Fornander and Olle Stål
  Comprehensive Genomic and Transcriptomic Analysis of the 11q13 Amplicon in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 820S-821S
  CANCER RESEARCH, 2009.


Ph.D. Theses

Josefine Bostner
  The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations: a crosstalk with potential to predict tamoxifen resistance in breast cancer
  2013.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.